Saama and iNDX.Ai Launch New COVID-19 Command Center


Applied Clinical Trials

Saama Technologies, Inc., the AI clinical analytics platform company, and iNDX.Ai, a Multi-omics Data Analytics and translational research platform company, have announced the launch of the new COVID-19 Command Center. The COVID-19 Command Center, based on a combination of Saama’s Life Science Analytics Cloud (LSAC) and iNDX.Ai’s iCore Platform, is a purpose-built, therapeutic area-specific data analytics platform that will accelerate the ability of life sciences companies to expedite internal research and development programs for therapies to prevent and treat COVID-19. 

Many biopharma organizations are sharing COVID-19 research data through organizations such as the recently established EndPandemic National Data Consortium, which six companies-including Saama and iNDX.Ai-have joined. The COVID-19 Command Center was created to provide sponsors pursuing in-house COVID-19 clinical development efforts only with the same AI-powered data analytics platform being used by the EndPandemic National Data Consortium. The COVID-19 Command Center includes patient data from ongoing COVID-19 clinical trials in China, South Korea, and the U.S. with nearly 8,500 patients, including over 3,000 positive cases. The COVID-19 Command Center delivers all the multiomics and clinical data analytics needed to manage COVID-19 clinical studies. From preclinical development to approval, researchers can optimize study design, patient selection, site activation, and scientific analysis by dynamically visualizing, analyzing, and interrogating data faster than ever before.  

“Saama wants all life science companies, whether they are engaged in public or private research efforts, to have access to the best possible analytics platform so they can expedite promising COVID-19 clinical trials and bring critical vaccines and treatments to the market as soon as possible,” said Suresh Katta, Founder and CEO of Saama Technologies. “The COVID-19 Command Center, the first offering from Saama’s purpose-built Command Center strategy, is customized to meet needs related to research on the novel coronavirus but can also be used more broadly for other infectious disease clinical development efforts now and in the future.” 

“iNDX.Ai believes that AI-enabled, multi-model deep and dense data analytics will help biopharma companies accelerate their translational research in clinical trials to deliver therapies that could potentially treat and prevent COVID-19,” said Mohan Uttarwar, CEO of iNDX.Ai. “The COVID-19 Command Center ensures that every life science company, whether engaged in solo or collaborative research, will be able to apply data analytics to inform and advance their research and help end the pandemic. By partnering on the COVID-19 Command Center, iNDX.Ai and Saama provide an end-to-end clinical development solution, from in silico biomarker discovery to Investigational New Drug (IND) application submission.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.